NDAINHALATIONPOWDER
Approved
Dec 2018
Lifecycle
Peak
Competitive Pressure
0/100
Clinical Trials
20
Data completeness
6/8 — Strong
INBRIJA (levodopa) by Merz Therapeutics is levodopa, the metabolic precursor of dopamine, crosses the blood-brain barrier and presumably is converted to dopamine in the brain. First approved in 2018.
Drug data last refreshed 7h ago · AI intelligence enriched 1mo ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
INBRIJA is an inhaled levodopa powder approved in December 2018 for Parkinson's disease, representing a novel inhalation route for a classic dopaminergic therapy. Levodopa crosses the blood-brain barrier and is converted to dopamine, relieving motor symptoms of Parkinson's disease. This formulation enables rapid, non-invasive drug delivery during OFF episodes in patients already on oral levodopa therapy.
$0.027BPart D
Peak7.0 years to LOEProduct is at peak lifecycle stage with $27M in annual Part D spending and 8,730 claims in 2023, indicating established market presence with stable brand team requirements.
Mechanism of Action
Levodopa, the metabolic precursor of dopamine, crosses the blood-brain barrier and presumably is converted to dopamine in the brain. This is thought to be the mechanism whereby levodopa relieves symptoms of Parkinson's disease.
Pharmacologic Class:
Aromatic Amino Acid
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (20)
Real-world Patient Experiences With Inbrija®
Started Sep 2026
120 enrolled
Parkinson Disease (PD)Parkinson's DiseaseOff Episodes of Parkinson Disease
Real-World Study of Foslevodopa/Foscarbidopa to Assess Quality of Life Outcomes in Adult Participants Earlier Within Advanced Parkinson Disease
Started Aug 2026
100 enrolled
Parkinson's Disease
Long Term Effectiveness of Levodopa-Entacapone-Carbidopa Intestinal Gel in Participants With Advanced Parkinson's Disease
Started May 2026
1 enrolled
Advanced Parkinson Disease
A Study to Assess Change in Disease Symptoms in Adult Participants With Advanced Parkinson Disease Using Subcutaneous Foslevodopa/Foscarbidopa in Belgium
Started Mar 2026
120 enrolled
Parkinson's Disease
A Study to Evaluate the Effectiveness of Two Doses of AP-472 as Adjunctive Therapy to Levodopa in Parkinson's Disease (PD) Participants With Motor Fluctuations
Started Feb 2026
150 enrolled
Parkinson Disease
Worked on INBRIJA at Merz Therapeutics? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.